Dr. Kalmar is currently Executive Director, Operations for Genome BC and has held this role since 2004. Prior to his role at Genome BC, Dr. Kalmar was engaged in strategic consulting activities with several early stage pharmaceutical companies which included overseeing operations, implementing technology development and providing merger and acquisition planning. From 1996 to 2002 Dr. Kalmar held senior management positions with Kinetek Pharmaceuticals Inc., a privately held Vancouver-based biopharmaceutical company that was acquired by QLT in March, 2004. During this time Dr. Kalmar established and managed multiple external collaborations with academics and clinicians in the areas of signal transduction, preclinical studies and technology access.
Dr. Kalmar obtained his undergraduate science degree from the University of British Columbia and his Ph.D. in Biology from Simon Fraser University.
